Study on the Mechanism of Ginseng and Liquorice on Non-small Cell Lung Cancer Based on Network Pharmacology and <i>in Vitro</i> Experiments

ZHOU Wenyue; WEN Yiru; ZHOU Senlin; WANG Mengqi; TONG Yu; XU Guangya; SHI Zheng

doi:10.13386/j.issn1002-0306.2022100268

Volume 44 Issue 16

Aug. 2023

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2023 > 44(16): 25-33. > DOI: 10.13386/j.issn1002-0306.2022100268

ZHOU Wenyue, WEN Yiru, ZHOU Senlin, et al. Study on the Mechanism of Ginseng and Liquorice on Non-small Cell Lung Cancer Based on Network Pharmacology and in Vitro Experiments[J]. Science and Technology of Food Industry, 2023, 44(16): 25−33. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022100268.

Citation:

PDF (8106 KB)

Study on the Mechanism of Ginseng and Liquorice on Non-small Cell Lung Cancer Based on Network Pharmacology and in Vitro Experiments

1.
Clinical Medical College/Affiliated Hospital, College of Food and Bioengineering, School of Pharmacy, School of Preclinical Medicine, Chengdu University, Chengdu 610106, China
2.
West China Hospital, Sichuan University, Chengdu 610041, China

More Information

Received Date: October 27, 2022
Available Online: June 19, 2023

Graphical Abstract

Abstract

Abstract

Objective: The study was to investigate the potential mechanisms and preliminarily pharmacological effects of ginseng-licorice in the treatment of non-small cell lung cancer (NSCLC) by network pharmacology and in vitro experiments. Methods: Firstly, the active components and potential targets of ginseng-licorice were screened by using the traditional Chinese medicine system pharmacology database and analysis platform (TCMSP), and the drug-components-target map was constructed using Cytoscape 3.7.1 software. TDD (Therapeutic Target Database), CTD (Comparative Toxicogenomics Database) and Gene Cards (The Human Gene Database) were used to obtain targets for NSCLC, and disease-drug intersection targets were obtained. Protein Interaction Network (PPI) was established by database STRING and Cytoscape software. Combined with PPI, GO and KEGG, the overall analysis was conducted to determine the main pathway and key targets of ginseng-licorice in the treatment of NSCLC. Finally, the anti-tumor effect of ginseng-licorice on NSCLC was verified by MTT colorimetric assay and flow cytometry. Results: The AKT1, TP53, CASP3 and VEGFA should be the potential targets for the treatment of NSCLC 122 targets of "ginseng-licorice" -NSCLC intersection was obtained from the screening of TTD, CTD and gene cards databases. Combined with the comprehensive analysis of PPI, GO and KEGG, the key targets of ginseng and licorice on NSCLC were identified as AKT1, TP53, IL, AMPK and TNF. The results of in vitro experiments showed that the drug to ginseng-licorice could significantly inhibit the proliferation of human non-small cell lung cancer cells, and could induce tumor cell apoptosis, thereby exerting an anti-tumor effect. Conclusion: This study initially explored the potential mechanisms and preliminarily pharmacological effects of the active ingredients of ginseng-licorice on NSCLC, providing a new theoretical basis for the clinical application of drug for the treatment of ginseng-licorice in the treatment of non-small cell lung cancer.
- network pharmacology,
- non-small cell lung cancer,
- ginseng,
- licorice

FullText(HTML)

References (36)

References

[1]	RELLI V, TREROTOLA M, GUERRA E, et al. Abandoning the notion of non-small cell lung cancer[J]. Trends Mol Med,2019,25(7):585−594. doi: 10.1016/j.molmed.2019.04.012
[2]	孙玲玲, 陈芝强, 张弛, 等. 中医药对比化疗维持治疗中晚期非小细胞肺癌的系统综述[J]. 中医肿瘤学杂志,2020,2(5):74−80. [SUNL L L, CHEN Z Q, ZHANG C, et al. Systematic review on clinical efficacy of Chinese medicine maintenance treatment versus chemotherapy maintenance treatment for advanced non-small cell lung cancer[J]. Journal of Oncology in Chinese Medicine,2020,2(5):74−80. SUNL L L, CHEN Z Q, ZHANG C, et al. Systematic review on clinical efficacy of Chinese medicine maintenance treatment versus chemotherapy maintenance treatment for advanced non-small cell lung cancer[J]. Journal of Oncology in Chinese Medicine, 2020, 2(5): 74-80.
[3]	YOH K, GOTO Y, NAITO Y, et al. Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting[J]. Anticancer Res,2017,37(3):1507−1513. doi: 10.21873/anticanres.11478
[4]	VISSER S, HUISBRINK J, VAN 'T VEER N E, et al. Renal impairment during pemetrexed maintenance in patients with advanced non-small cell lung cancer: A cohort study[J]. Eur Respir J,2018,52(4):1800884. doi: 10.1183/13993003.00884-2018
[5]	邢蓓蓓, 程海波, 沈卫星. 药食同源中药在肿瘤预防中的应用探讨[J]. 四川中医,2018,36(2):46−48. [XING B B, CHENG H B, SHEN W X. Application discussion of edible source of Chinese materia medica used in malignant tumor prevention[J]. Journal of Sichuan of Traditional Chinese Medicine,2018,36(2):46−48. XING B B, CHENG H B, SHEN W X. Application discussion of edible source of Chinese materia medica used in malignant tumor prevention[J]. Journal of Sichuan of Traditional Chinese Medicine, 2018, 36(2): 46-48.
[6]	单峰, 黄璐琦, 郭娟, 等. 药食同源的历史和发展概况[J]. 生命科学,2015,27(8):1061−1069. [DAN F, HUANG L Q, GUO J, et al. History and development of "One Root of Medicine and Food"[J]. Chinese Bulletin of Life Sciences,2015,27(8):1061−1069. DAN F, HUANG L Q, GUO J, et al. History and development of "One Root of Medicine and Food"[J]. Chinese Bulletin of Life Sciences, 2015, 27(8): 1061-1069
[7]	庞婷, 麦蓝尹, 陈勇, 等. 中药药对配伍的化学成分变化研究进展[J]. 中药材,2015,38(11):2429−2434. [PANG T, MAI L Y, CHEN Y, et al. Research progress on the chemical composition changes of traditional Chinese medicine pairs[J]. Journal of Chinese Medicinal Materials,2015,38(11):2429−2434. PANG T, MAI L Y, CHEN Y, et al. Research progress on the chemical composition changes of traditional Chinese medicine pairs[J]. Journal of Chinese Medicinal Materials, 2015, 38(11): 2429-2434.
[8]	KIM J M, KIM K S, LEE Y W, et al. Anti-angiogenic effects of water extract of a formula consisting of Pulsatilla koreana, Panax ginseng and Glycyrrhiza uralensis[J]. Zhong Xi Yi Jie He Xue Bao,2011,9(9):1005−1013. doi: 10.3736/jcim20110912
[9]	POPOVICH D G, YEO S Y, ZHANG W. Ginseng (Panax quinquefolius) and Licorice (Glycyrrhiza uralensis) root extract combinations increase hepatocarcinoma cell (Hep-G2) viability[J]. Evid Based Complement Alternat Med,2011,2011:408273.
[10]	LU J M, YAO Q, CHEN C. Ginseng compounds: An update on their molecular mechanisms and medical applications[J]. Curr Vasc Pharmacol,2009,7(3):293−302. doi: 10.2174/157016109788340767
[11]	LIU T, ZUO L, GUO D, et al. Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway[J]. Biomed Pharmacother,2019,120:109483. doi: 10.1016/j.biopha.2019.109483
[12]	张耀峰. 甘草及其活性成分的药理活性研究进展[J]. 中医临床研究,2019,11(9):141−142. [ZHANG Y F. Research progress on pharmacological activities of Glycyrrhiza uralensis Fisch and its active components[J]. Clinical Journal of Chinese Medicine,2019,11(9):141−142. ZHANG Y F. Research progress on pharmacological activities of Glycyrrhiza uralensis Fisch and its active components[J]. Clinical Journal of Chinese Medicine, 2019, 11(9): 141-142.
[13]	HAN Y J, KANG B, YANG E J, et al. Simultaneous determination and pharmacokinetic characterization of glycyrrhizin, isoliquiritigenin, liquiritigenin, and liquiritin in rat plasma following oral administration of Glycyrrhizae radix extract[J]. Molecules,2019,24(9):1816. doi: 10.3390/molecules24091816
[14]	ZHU J, HUANG R, YANG R, et al. Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8⁺ T cell infiltration[J]. Cancer Cell Int,2021,21(1):529. doi: 10.1186/s12935-021-02223-0
[15]	BOEZIO B, AUDOUZE K, DUCROT P, et al. Network-based approaches in pharmacology[J]. Mol Inform, 2017, 36(10): 1700048.
[16]	廖景光, 李敏妍, 谢兆丰, 等. 人参皂苷Rg1配伍丹参酮IIA对缺氧-复氧H9c2细胞的保护作用及机制研究[J]. 中国现代医学杂志,2014,24(22):13−16. [LIAO J G, LI M Y, XIE Z F, et al. Protective effects and mechanisms of ginsenoside Rg1 combined with tanshinone IIA on H9c2 cells treated byhypoxia-reoxygenation[J]. China Journal of Modern Medicine,2014,24(22):13−16. LIAO J G, LI M Y, XIE Z F, et al. Protective effects and mechanisms of ginsenoside Rg1combined with tanshinone IIA on H9c2 cells treated byhypoxia-reoxygenation[J]. China Journal of Modern Medicine, 2014, 24(22): 13-16.
[17]	张春晶, 于海涛, 侯金才, 等. S型与R型人参皂苷Rh_2对人肺腺癌A549细胞增殖和凋亡的影响[J]. 中国中药杂志,2011,36(12):1670−1674. [ZHANG C J, YU H T, HOU J C, et al. Effects of 20(S)-ginsenoside Rhz and 20(R)-ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells[J]. China Journal of Modern Medicine,2011,36(12):1670−1674. ZHANG C J, YU H T, HOU J C, et al. Effects of 20(S)-ginsenoside Rhz and 20(R)-ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells[J]. China Journal of Modern Medicine, 2011, 36(12): 1670-1674.
[18]	LEE W Y, LEE C Y, KIM Y S, et al. The methodological trends of traditional herbal medicine employing network pharmacology[J]. Biomolecules,2019,9(8):362. doi: 10.3390/biom9080362
[19]	王永宏, 艾芷伊, 张俊顺, 等. 人参皂苷抗肿瘤活性与机制研究进展[J]. 食品工业科技,2023,44(1):485−491. [WANG Y H, AI Z Y, ZHANG J S, et al. Research progress on antitumor activity and mechanism of ginsenosides[J]. Science and Technology of Food Industry,2023,44(1):485−491. WANG Y H, AI Z Y, ZHANG J S, et al. Research progress on antitumor activity and mechanism of ginsenosides[J]. Science and Technology of Food Industry, 2023, 44(1): 485-491
[20]	张芳红, 朱公建, 王晓敏, 等. 甘草查尔酮B对人非小细胞肺癌A549细胞增殖和凋亡的影响[J]. 甘肃医药,2022,41(5):385−388,422. [ZHANG F H, ZHU G J, WANG X M, et al. The effects of licochalcone B on cell growth and apoptosis in A549 non-small cell lung cancer cells[J]. Gansu Medical Journal,2022,41(5):385−388,422. ZHANG F H, ZHU G J, WANG X M, et al. The effects of licochalcone B on cell growth and apoptosis in A549 non-small cell lung cancer cells[J]. Gansu Medical Journal, 2022, 41(5): 385-388, 422
[21]	BRENNAN B T C M A. Pro-inflammatory programmed cell death[J]. Trends in Microbiology,2001,9(3):113−114.
[22]	HU S, GE M, ZHANG S, et al. Integrated network pharmacology and experimental verification to explore the molecular mechanism of Hedysarum multijugum Maxim-Curcumae Rhizoma Herb pair for treating non-small cell lung cancer[J]. Front Oncol,2022,12:854596. doi: 10.3389/fonc.2022.854596
[23]	赵粤. 非小细胞肺癌肺气虚证小鼠模型及黄芪、半枝莲药对干预的菌群-代谢机制研究[D]. 济南: 山东中医药大学, 2021 ZHAO Y. Study on mice model of lung qi deficiency syndrome of non-small cell lung cancer and the intestinal flora-host metabolism mechanism of astragalus membranaceus and scutellariae barbataon intervention[D]. Jinan: Shandong University of Traditional Chinese Medicine, 2021.
[24]	赵梦倩. 芪莲合剂对肺脾气虚型中晚期NSCLC患者临床疗效的观察及芪莲药对抑制A549细胞增殖的活性成分筛选[D]. 济南: 山东中医药大学, 2021 ZHAO M Q. Observation on the clinical effect of QiLian mixture onpatients with pulmonary qi deficiency type and advanced NSCLC and screening of active ingredients of QiLian medicine toinhibit the proliferation of A549 cells[D]. Jinan: Shandong University of Traditional Chinese Medicine, 2021.
[25]	FREDERICK M I, SIDDIKA T, ZHANG P, et al. MiRNA-dependent regulation of AKT1 phosphorylation[J]. Cells,2022,11(5):821. doi: 10.3390/cells11050821
[26]	BALASURIYA N, MCKENNA M, LIU X, et al. Phosphorylation-dependent inhibition of AKT1[J]. Genes (Basel),2018,9(9):450. doi: 10.3390/genes9090450
[27]	OLIVIER M, HUSSAIN S P, CARON DE FROMENTEL C, et al. TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer[J]. IARC Sci Publ,2004(157):247−270.
[28]	RICE S J, LIU X, ZHANG J, et al. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling[J]. Lung Cancer,2019,131:58−61. doi: 10.1016/j.lungcan.2019.03.014
[29]	VARFOLOMEEV E, VUCIC D. Intracellular regulation of TNF activity in health and disease[J]. Cytokine,2018,101:26−32. doi: 10.1016/j.cyto.2016.08.035
[30]	HUANG Q, LI F, LIU X, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy[J]. Nat Med,2011,17(7):860−866. doi: 10.1038/nm.2385
[31]	MUKAI M, KUSAMA T, HAMANAKA Y, et al. Cross talk between apoptosis and invasion signaling in cancer cells through caspase-3 activation[J]. Cancer Res,2005,65(20):9121−9125. doi: 10.1158/0008-5472.CAN-04-4344
[32]	DUFFY M J, O'GRADY S, TANG M, et al. MYC as a target for cancer treatment[J]. Cancer Treat Rev,2021,94:102154. doi: 10.1016/j.ctrv.2021.102154
[33]	GEORGE B, GUI B, RAGURAMAN R, et al. AKT1 transcriptomic landscape in breast cancer cells[J]. Cells, 2022, 11(15): 2290.
[34]	KORPANTY G J, KAMEL-REID S, PINTILIE M, et al. Lung cancer in never smokers from the princess margaret cancer centre[J]. Oncotarget,2018,9(32):22559−22570. doi: 10.18632/oncotarget.25176
[35]	FISCHER R, KONTERMANN R E, PFIZENMAIER K. Selective targeting of TNF receptors as a novel therapeutic approach[J]. Front Cell Dev Biol,2020,8:401. doi: 10.3389/fcell.2020.00401
[36]	KANDASAMY K, SRIVASTAVA R K. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells[J]. Cancer Res,2002,62(17):4929−4937.

Supplements (0)

Cited By

Cited by

Periodical cited type(4)

1.	关玉婷，温思萌，冯雪，白云鹏，陈瑞瑞，沈晓勇，冯佳宁，常世敏，程鑫颖. 茯苓渣多糖组成分析及体外抗癌、免疫活性研究. 食品工业科技. 2022(21): 381-387 . 本站查看
2.	李霞，刘承鑫，黄艳，莫观兰，关媛. 碱提西番莲叶多糖的分离、鉴定及生物活性. 食品与机械. 2021(03): 137-143 .
3.	钱艳艳，王丽，文春南，周艳，李晓，张丽先，周贤宇，麻兵继. 鲜地黄低聚糖纯化及其理化特性和抗氧化活性研究. 天然产物研究与开发. 2021(09): 1470-1477 .
4.	王峙力，王鑫，韩烨，谢越，马永强. 甜玉米芯硒多糖的制备及其对淀粉酶抑制作用. 包装工程. 2021(21): 33-41 .